Skip to content

Trial · Interventional

Not yet recruitingPhase 4Registry data

RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

NCTNCT07301437 (opens ClinicalTrials.gov in a new tab)Other idKY-2025-202
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Not yet recruiting
Phase
Phase 4
Enrollment
120 participants (estimated)
Sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Other
Design
Randomized · Open label (no masking)
Countries
Not stated
Start
1 May 2026 (estimated)
Primary completion
31 Aug 2027 (estimated)
Completion
31 Aug 2027 (estimated)
First posted
24 Dec 2025
Last update posted
23 Mar 2026
Conditions
Overweight and Obese Adults

Timeline

1 trial · 1 not yet recruiting

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202620272028
  1. Ph 4

    RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

    NCT07301437

    est. 1 May 2026 to est. 31 Aug 2027

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.

Interventions

  • liraglutide monotherapyDrug
  • liraglutide combined with orlistatDrug

Arms2

  • Experimental

    experimental group

  • Active comparator

    control group

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. weight loss

    Time frame · 6 months

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 65 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * BMI: ≤ 35 kg/m² and ≥ 30 kg/m², or ≥ 27 kg/m² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia) * Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up. * No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements. Exclusion Criteria: * Allergy to liraglutide, orlistat or excipients * Severe liver and kidney dysfunction: ALT or AST\> three times the upper limit of normal, or eGFR \<30 mL/min * Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism/hypothyroidism * Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers * Pregnant or lactating women * Others: Type 1 diabetes, malignant tumors, severe cardiovascular diseases (such as NYHA IV).

PepBank is a research reference. Talk to a doctor before you use any peptide.